New safety check for Kids' leukemia drug BESPONSA
NCT ID NCT06476665
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is checking the safety of the drug BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL). The 10 participants have already been treated and are being watched for side effects, especially liver problems. The goal is to better understand the risks of this approved drug in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BESPONSA (inotuzumab ozogamicin)
What this could lead to
If successful, this study could confirm that BESPONSA is safe for children with a certain type of leukemia, supporting its continued use.
What could go wrong
This is a small, observational safety study with only 10 participants, so results may not apply to all patients. There is a known risk of liver problems with this drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan